Compare ESI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | BMRN |
|---|---|---|
| Founded | 1922 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.5B |
| IPO Year | 2014 | 1999 |
| Metric | ESI | BMRN |
|---|---|---|
| Price | $42.52 | $54.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 18 |
| Target Price | $35.56 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 2.6M | 1.5M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.79 | ★ 1.80 |
| Revenue | ★ $2,551,200,000.00 | $1,313,646,000.00 |
| Revenue This Year | $21.24 | $15.02 |
| Revenue Next Year | $7.34 | $12.23 |
| P/E Ratio | $49.15 | ★ $29.59 |
| Revenue Growth | 3.84 | ★ 17.62 |
| 52 Week Low | $20.43 | $50.76 |
| 52 Week High | $41.20 | $66.28 |
| Indicator | ESI | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 70.75 | 44.61 |
| Support Level | $24.31 | $53.45 |
| Resistance Level | N/A | $56.21 |
| Average True Range (ATR) | 1.49 | 1.34 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 86.07 | 45.31 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.